Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

Milder side ef­fects among the el­der­ly were crit­i­cal in Pfiz­er and BioN­Tech’s choice of vac­cine can­di­date to send in­to Phase III test­ing, the com­pa­nies re­vealed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER